Novartis AG (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 144   

Articles published

NVS 102.46 -0.85 (-0.82%)
price chart
Novartis AG (ADR) Partners With Aduro Biotech With A $750 Million Deal
Novartis AG (ADR) (NYSE:NVS) has announced a deal with cancer immunotherapy company, Aduro Biotech, Inc., in which both the companies will partner to research and manufacture treatments for cancer.
Novartis AG (ADR) Inks $750 Million Deal With Aduro Biotech  Bidness ETC
Novartis AG (ADR) Receives FDA Approval For Jadenu Tablets
Novartis AG (ADR) (NYSE:NVS) was granted approval on Monday by the US Food and Drug Administration (FDA) for their new once-daily, oral formulation of Exjade (deferasirox) called Jadenu.
Arrowhead Research Corp To Acquire Novartis AG (ADR) RNAi Assets
Arrowhead Research Corp (NASDAQ:ARWR), which develops targeted RNAi therapeutics, announced Thursday that it will acquire Novartis AG's (ADR) (NYSE:NVS) RNAi research and development portfolio and other assets in efforts to strengthen its work in ...
Top Gainers Under Review - Vertex Pharmaceuticals Incorporated (NASDAQ ...  wsnewspublishers
Stocks in Momentum: Arrowhead Research Corp. (NASDAQ:ARWR), Vertex ...  StreetWise Report
Novartis AG (ADR) Ordered To Halt Some Japanese Operations
The Japanese Health Ministry has ordered Novartis AG ADR (NYSE: NVS) to halt most of its operations in Japan for 15 days in March, claiming that the company had failed to report side-effects caused by its products within a pre-specified time.
Novartis AG (ADR) Zarxio Becomes First Biosimilar Approved For Sale In US
Novartis AG (ADR) (NYSE:NVS) on Friday won the US Food and Drug Administration's (FDA) approval for its biosimilar drug Zarxio, a cheaper imitation version of Amgen, Inc.'s (NASDAQ:AMGN) Neupogen, making Zarxio the first ever biosimilar to be ...
GlaxoSmithKline plc (ADR) To Close Asset Swap Deal With Novartis AG (ADR ...
GlaxoSmithKline plc (ADR) (NYSE:GSK) announced on Wednesday that it anticipates closing the mega-billion dollar asset exchange with Novartis AG (ADR) (NYSE:NVS) in the week beginning March 2, 2015. However, the deal, which is expected to make ...
Novartis AG (NYSE:NVS) & GlaxoSmithKline PLC (NYSE:GSK) Receive a Green ...  WallStreet.org
Bristol-Myers Squibb Co, Sanofi SA (ADR), and Novartis AG (ADR) Lead 2015 ...
Bristol-Myers Squibb Co (NYSE:BMY), Sanofi SA (ADR)(NYSE:SNY), and Novartis AG's (ADR)(NYSE:NVS) will be 2015's most valuable new drug launches, says a report published on Monday.
New Blockbuster Drugs Expected From Sanofi SA (ADR) (NYSE:SNY), Bristol ...  NYSE Post
Amgen, Inc. Petition Against Novartis AG (ADR) Denied By Court- Biosimilar ...
A US judge has struck down Amgen Inc.'s (NYSE:AMGN) petition to prevent Novartis AG ADR (NYSE:NVS) launching a biosimilar version of its blockbuster neutropenia treatment drug, Neupogen, in the US.
Zarxio, Novartis AG (ADR) (NYSE:NVS) Biosimilar Drug Gets Approved by FDA
Zarxio, the bio similar drug manufactured by Novartis AG (ADR) (NYSE:NVS) got approved by the US Food and Drug Administration, last Friday.
Biosimilars the Way Forward: Companies in Focus - Analyst Blog  Nasdaq
Latest Insights on Amgen, Inc.(NASDAQ:AMGN)  Investor Newswire
Novartis AG (ADR) Wins FDA Approval For Blood Cancer Drug
Novartis AG (ADR) (NYSE: NVS) has won the US Food and Drug Administration's (FDA) approval for its new blood-cancer treatment drug, Farydak.
Novartis' Farydak Approved for Multiple Myeloma with Warning - Analyst Blog  Nasdaq